1	Methods US Adults Used to Stop Smoking, 2021–2022
2	
3	Floe Foxon <sup>1</sup> , BSc (Hons); Ray Niaura <sup>2</sup> , PhD
4	<sup>1</sup> Department of Data Management and Statistical Analysis, Pinney Associates, Pittsburgh, Pennsylvania
5	<sup>2</sup> Department of Epidemiology, School of Global Public Health, New York University, New York, New York
6	Corresponding Author: Floe Foxon ( <u>ffoxon@pinneyassociates.com</u> )
7	
8 9	Abstract
10	Nationally representative Centers for Disease Control and Prevention (CDC) survey data
11	were used to identify which subpopulations of US adults had stopped smoking cigarettes for 6
12	months or longer in the last year and the methods they used. From 2021 through 2022, 2.9 million
13	adults stopped smoking. Most of these were male, non-Hispanic White, aged less than 55 years,
14	college educated, and identified as straight. The most popular method used was nicotine products
15	(53.9%; 1.5 million adults), especially e-cigarettes in combination with other methods (40.8%; 1.2
16	million) and e-cigarettes alone (26.0%; 0.7 million). The data suggest that interventions to reduce
17	smoking could focus on subpopulations that stopped smoking the least and encourage use of
18	evidence-based methods.

# 20 Introduction

21 Although considerable progress has been made in the last decade in the US to reduce 22 prevalence of combustible cigarette smoking [1], smoking continues as one of the leading causes of 23 chronic disease [2]. Thus, further reductions in smoking prevalence are crucial to preventing or 24 reducing the effects of chronic disease in the US. A previous study identified giving up cigarettes all 25 at once, gradually cutting back on cigarettes, and substituting some cigarettes with e-cigarettes as 26 the most commonly reported stop-smoking methods during quit attempts from 2014 through 2016 27 [3]. More recent data are needed to understand who stopped smoking since 2016 and how they did 28 it. The objectives of this study were to identify which subpopulations stopped smoking completely 29 (reported having stopped smoking for  $\geq 6$  months in the past year as defined in previous research 30 [4]) or tried to stop smoking, and to quantify the methods they used by using the most recent CDC 31 National Health Interview Survey (NHIS) data [5].

#### 32 Methods

33 Data on methods used to stop smoking were sourced from CDC's latest NHIS. These data are 34 nationally representative and have low bias [5]. The 2022 NHIS (fielded January–December 2022) 35 asked respondents who had stopped smoking in the past 2 years which methods they used to stop 36 smoking completely. These analyses focused on those respondents who had stopped smoking in the 37 last year (2021 through 2022) and who had stopped smoking for 6 months or longer at the time of 38 the survey. The survey also asked respondents who were still smoking but had tried to stop in the 39 past year which methods they used when they tried. Full details of questionnaire wording are 40 available in online supplemental materials (https://doi.org/10.17605/osf.io/HGMN6). The 41 prevalence of each stop-smoking method was calculated with NHIS sampling weights to provide 42 nationally representative population estimates. NHIS stratum and cluster variables were also used

to provide 95% CIs. Demographic characteristics of the sample of adults who stopped smoking or
tried to stop (sex, race or ethnicity, age, education, and sexual orientation) were derived from
standard NHIS questions, similar to other CDC NHIS publications [6, 7].
Only publicly available, de-identified survey data were used; therefore, this study is exempt
from NIH human subjects research under NIH exemption 4 and did not require institutional review

- 48 board review.
- 49 Results

50 Overall, 2.9 million US adults stopped smoking from 2021 through 2022 and had been 51 stopped for 6 months or longer at the time of the survey. In the same period, 13.1 million tried to 52 stop but were unsuccessful. Slightly more men stopped smoking than women (1.6 million vs 1.3 53 million); most were non-Hispanic White adults, most were aged younger than 55 years, most had at 54 least some college education, and most self-identified as straight (Table 1). Among those who 55 stopped smoking for 6 months or longer, the most commonly reported methods used were nicotine 56 products (53.9%, 1.5 million US adults), primarily e-cigarettes used alone or in combination with 57 other methods (40.8%, 1.2 million US adults; Table 2). The least commonly reported methods were 58 non-nicotine, non-prescription drug methods (including a guit line, counseling or clinic, class, or 59 group) (6.3%, 0.2 million US adults). Of the listed methods, the most commonly reported exclusive 60 method selected was e-cigarettes; 26.0% (0.7 million US adults) of adults who stopped smoking 61 from 2021 through 2022 for 6 months or longer selected e-cigarettes as their only listed method.

#### 62 Discussion

This study identified subpopulations of US adults in NHIS 2022 who stopped or tried to stop
 smoking and the methods they used. Results showed that smaller proportions of all adults who

stopped smoking from 2021 through 2022 were women, Hispanic and non-Hispanic non-White,
older (aged ≥55 y), had lower educational attainment (less than some college education), and were
non-heterosexual. This may be explained simply by relative subpopulation size (i.e., the US adult
population comprises fewer non-heterosexual adults compared to heterosexual adults and more
males who smoke than females [8]). Nevertheless, it is important to ensure that specific
subpopulations do not get left behind in efforts to curb smoking.

71 Approximately 40% of adults surveyed in NHIS did not report using any of the surveyed 72 evidence-based methods to stop smoking. Methods containing nicotine, primarily e-cigarettes, were 73 the most commonly-reported methods that were explicitly surveyed. This may provide support for 74 FDA's "nicotine-focused framework for public health" [9], which describes noncombustible nicotine 75 products as "a promising foundation for a comprehensive approach to tobacco harm reduction," 76 FDA's efforts to authorize certain e-cigarette products as "appropriate for the protection of public 77 health" [10], and CDC's statement that "[e]-cigarettes have the potential to benefit adults who 78 smoke ... if used as a complete substitute for regular cigarettes," [11] while necessarily preventing 79 access to nicotine products by nonsmoking subpopulations, such as adolescents.

This study's strengths include use of a large, nationally representative survey with low bias administered by CDC. NHIS results are thought to be generalizable to the entire US population, because that is the purpose of its sample design by CDC's National Center for Health Statistics [5, 12]. Another strength is the direct measures of stopping smoking (i.e., survey questions answered by adults who actually stopped smoking) as opposed to indirect measures of stopping smoking (e.g., models).

86 This study also has limitations. First is the inability to parse out individual methods in the
87 "none of the above" category, which is an unavoidable limitation of the NHIS questionnaire design.
88 Because "none of the above" was inferred from respondents who stopped or tried but who did not

89	select any of the surveyed items, the "none of the above" category may be underrepresented in
90	these analyses. Furthermore, the questionnaire did not ask respondents about the duration of
91	treatment use. Future questionnaires should ask respondents for these details. Recall bias may also
92	limit the accuracy of these findings [13].
93	In conclusion, efforts to reduce smoking among US adults should focus on the
94	subpopulations that stopped smoking the least and encourage use of evidence-based methods.
95	Acknowledgements
96	An early version of this research was presented in poster form at the 2024 Society for
97	Research on Nicotine and Tobacco (SRNT) annual meeting
98	(https://doi.org/10.31219/osf.io/2yuw4). The authors thank two anonymous reviewers and
99	participants at the 2024 SRNT meeting for helpful comments and suggestions. This work received
100	no financial support.
101	The authors declare the following potential conflicts of interests: F.F. provides consulting
102	services through Pinney Associates on tobacco harm reduction on an exclusive basis to Juul Labs
103	Inc, which had no involvement in this article. R.N. has received grant and contractual funding from
104	the National Institutes of Health and the Food and Drug Administration; served as a paid consultant
105	to the Government of Canada via a contract with Industrial Economics Inc; received an honorarium
106	for a virtual meeting from Pfizer Inc; received other NIDA grants paid to his employers; received
107	salary from the Steven Schroeder Institute for Tobacco Research and Policy Studies at The Legacy
108	Foundation, now Truth Initiative, New York University School of Global Public Health; and
109	communicated with Juul Labs personnel, for which there was no compensation, and received
110	hospitality in the form of meals at some meetings; none of which supported the work reported here.

## 111 References

- 113 1. Levy DT, Sánchez-Romero LM, Travis N, Yuan Z, Li Y, Skolnick S, et al. US nicotine vaping product
- 114 Simsmoke simulation model: the effect of vaping and tobacco control policies on smoking
- prevalence and smoking-attributable deaths. Int J Environ Res Public Health. 2021;18(9):4876.
- 116 PubMed <u>https://doi.org/10.3390/ijerph18094876</u>
- 117 2. Murray CJL, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M, et al. GBD 2019 Risk
- 118 Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019:
- a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223–
- 120 1249. PubMed <u>https://doi.org/10.1016/S0140-6736(20)30752-2</u>
- 121 3. Caraballo RS, Shafer PR, Patel D, Davis KC, McAfee TA. Quit methods used by US adult cigarette
- 122 smokers, 2014–2016. Prev Chronic Dis. 2017;14:E32. PubMed
- 123 https://doi.org/10.5888/pcd14.160600
- 124 4. Walton K, Wang TW, Prutzman Y, Jamal A, Babb SD. Characteristics and correlates of recent
- 125 successful cessation among adult cigarette smokers, United States, 2018. Prev Chronic Dis.
- 126 2020;17:E154. PubMed http://dx.doi.org/10.5888/pcd17.200173
- 127 5. Zablotsky B, Lessem SE, Gindi RM, Maitland AK, Dahlhamer JM, Blumberg SJ. Overview of the
- 128 2019 National Health Interview Survey questionnaire redesign. Am J Public Health.
- 129 2023;113(4):408–415. PubMed <u>https://doi.org/10.2105/AJPH.2022.307197</u>
- 130 6. Cornelius ME, Wang TW, Jamal A, Loretan CG, Neff LJ. Tobacco product use among adults —
- 131 United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(46):1736–1742. PubMed
- 132 <u>https://doi.org/10.15585/mmwr.mm6946a4</u>
- 133 7. Cornelius ME, Loretan CG, Wang TW, Jamal A, Homa DM. Tobacco product use among adults —
- 134 United States, 2020. MMWR Morb Mortal Wkly Rep. 2022;71(11):397–405. PubMed
- 135 <u>https://doi.org/10.15585/mmwr.mm7111a1</u>
- 136 8. Cornelius ME, Loretan CG, Jamal A, Davis Lynn BC, Mayer M, Alcantara IC, et al. Tobacco product
- 137 use among adults United States, 2021. MMWR Morb Mortal Wkly Rep. 2023;72(18):475–483.
- 138 PubMed <u>https://doi.org/10.15585/mmwr.mm7218a1</u>
- 139 9. Gottlieb S, Zeller M. A nicotine-focused framework for public health. N Engl J Med.
- 140 2017;377(12):1111–1114. PubMed <u>https://doi.org/10.1056/NEJMp1707409</u>

- 141 10. US Food and Drug Administration. Premarket tobacco product marketing granted orders.
- 142 Accessed January 26, 2024. <u>https://www.fda.gov/tobacco-products/premarket-tobacco-product-</u>
- 143 <u>applications/premarket-tobacco-product-marketing-granted-orders</u>
- 144 11. Centers for Disease Control and Prevention. About electronic cigarettes (e-cigarettes). Accessed
- 145 January 26, 2024.
- 146 <u>https://web.archive.org/web/20240102195530/https://www.cdc.gov/tobacco/basic information</u>
- 147 <u>/e-cigarettes/about-e-cigarettes.html</u>
- 148 12. Centers for Disease Control and Prevention; US Department of Health and Human Services,
- 149 Division of Health Interview Statistics, National Center for Health Statistics. National Health
- 150 Interview Survey 2022 survey description. Published 2023. Accessed January 26, 2024.
- 151 <u>https://ftp.cdc.gov/pub/Health Statistics/NCHS/Dataset Documentation/NHIS/2022/srvydesc-</u>
- 152 <u>508.pdf</u>
- 153 13. Borland R, Partos TR, Cummings KM. Systematic biases in cross-sectional community studies
- 154 may underestimate the effectiveness of stop-smoking medications. Nicotine Tob Res.
- 155 2012;14(12):1483–1487. PubMed <u>https://doi.org/10.1093/ntr/nts002</u>
- 156

# Table 1. Demographic Characteristics of Adults Who Stopped Smoking (N = 304), or Tried to Stop Smoking but Did Not Stop Smoking from 2021 through

2022 (N = 1,431), National Health Interview Survey  $2021-2022^{\circ}$ 

160

	Stopped smoking completely <sup>b</sup> , weighted % (95% CI) (weighted	Tried to stop smoking but did not stop smoking, weighted % (95%
Characteristic	N, millions)	CI) (weighted N, millions)
All adults	100 (2.9)	100 (13.1)
Sex		
Female	45.3 (39.3-51.4) (1.3)	44.2 (41.1-47.2) (5.8)
Male	54.7 (48.6-60.7 (1.6)	55.8 (52.8-58.9) (7.3)
Race or ethnicity		
Hispanic	15.2 (10.8-20.6) (0.4)	12.0 (9.9-14.4) (1.6)
Non-Hispanic Black	11.2 (7.5–15.9) (0.3)	16.1 (13.7–18.6) (2.1)
Non-Hispanic White	67.3 (60.8-73.2) (1.9)	65.1 (62.1-68.0) (8.5)
Non-Hispanic Other	6.3 (3.5–10.3) (0.2)	6.8 (5.4-8.6) (0.9)
Age, y		
18-34	41.9 (35.4-48.7) (1.2)	24.7 (21.9-27.6) (3.2)
35-54	34.2 (27.9-40.9) (1.0)	39.6 (36.4–42.8) (5.2)
55 or older	23.9 (19.0-29.3) (0.7)	35.7 (33.0-38.6) (4.7)
Education		
≤12 years (no diploma)	9.4 (5.8-14.2) (0.3)	18.5 (16.0-21.3) (2.4)
GED certificate or high school	34.4 (28.7-40.5) (1.0)	38.5 (35.5-41.7) (5.0)
diploma		
Some college (no degree)	18.8 (14.4-23.9) (0.5)	17.1 (15.1–19.3) (2.2)
Associate, undergraduate, or	37.3 (31.3-43.8) (1.1)	25.8 (23.2-28.5) (3.4)
graduate degree		
Sexual orientation		
Gay/lesbian/bisexual	12.8 (8.6-18.0) (0.4)	5.8 (4.5-7.4) (0.8)
Straight	82.8 (76.7-87.9) (2.4)	90.0 (88.1-91.7) (11.8)
Other	4.4 (1.8-8.8) (0.1)	4.1 (3.0-5.6) (0.5)

161

<sup>a</sup> Following Cornelius et al [8], modified Clopper-Pearson confidence limits were calculated by using the Korn
 and Graubard method.

<sup>164</sup> <sup>b</sup> Reported having stopped smoking for 6 months or longer in the past year, as defined in previous research

165 [4].

## 167 Table 2. Methods Used by Adults Who Stopped Smoking (N = 304), or Tried to

# 168 Stop Smoking but Did Not Stop Smoking (N = 1,431), National Health

- 169 Interview Survey, 2021–2022<sup>a</sup>
- 170

Method(s)	Stopped smoking completely <sup>b</sup> , weighted % (95% CI) (weighted N, millions)	Tried to stop smoking but did not stop smoking, weighted % (95% CI) (weighted N, millions)
Any method	100 (2.9)	100 (13.1)
Nicotine products		<b>``</b> ,
E-cigarettes	40.8 (34.4-47.5) (1.2)	20.7 (18.1-23.4) (2.7)
Exclusively <sup>c</sup>	26.0 (20.6-32.0) (0.7)	11.2 (9.3-13.3) (1.5)
Nicotine gum/lozenge	18.8 (14.1-24.4) (0.5)	19.0 (16.7-21.4) (2.5)
Exclusively <sup>c</sup>	d	4.8 (3.7-6.2) (0.6)
Nicotine patch	15.4 (11.1-20.6) (0.4)	22.1 (19.7-24.6) (2.9)
Exclusively <sup>c</sup>	5.4 (2.8-9.5) (0.2)	7.4 (6.1–9.0) (1.0)
Nicotine nasal spray/inhaler	d	0.9 (0.5-1.7) (0.1)
Exclusively <sup>c</sup>	d	d
One or more of the above	53.9 (47.4-60.3) (1.5)	45.1 (42.0-48.2) (5.9)
Prescription drug products		
Varenicline	5.1 (2.9-8.2) (0.1)	11.3 (9.5–13.3) (1.5)
Exclusively <sup>c</sup>	d	3.0 (2.1-4.2) (0.4)
Bupropion	4.7 (2.6-7.7) (0.1)	7.4 (5.9-9.0) (1.0)
Exclusively <sup>c</sup>	d	1.7 (1.0-2.7) (0.2)
One or more of the above	8.1 (5.3-11.8) (0.2)	16.2 (14.2-18.5) (2.1)
One or more pharmacotherapy	56.6 (49.9-63.1) (1.6)	51.1 (47.9-54.3) (6.7)
(nicotine product incl. e-		
cigarettes or prescription drug		
product)		
Non-nicotine, non-prescription		
drug methods		
Quit line	3.1 (1.4-5.7) (0.1)	4.3 (3.2-5.7) (0.6)
Exclusively <sup>c</sup>	3.1 (1.4-5.7) (0.1)	d
Counseling	3.1 (1.5-5.7) (0.1)	4.8 (3.6-6.2) (0.6)
Exclusively <sup>c</sup>	d	0.6 (0.3-1.2) (0.1)
Clinic/class/group	d	2.5 (1.7-3.5) (0.3)
Exclusively <sup>c</sup>	d	d
One or more of the above	6.3 (3.9–9.7) (0.2)	7.9 (6.4–9.7) (1.0)
Any of the above <sup>e</sup>	57.5 (50.8-63.9) (1.6)	52.5 (49.2-55.7) (6.9)
None of the above <sup>f</sup>	42.5 (36.1-49.2) (1.2)	47.5 (44.3-50.8) (6.2)

171

<sup>172</sup> <sup>a</sup> Following Cornelius et al [8], modified Clopper-Pearson confidence limits were calculated by using the Korn <sup>173</sup> and Graubard method

173 and Graubard method.

<sup>b</sup> Reported having stopped smoking for 6 months or longer in the past year, as defined in previous research
 [4].

<sup>176</sup> <sup>c</sup> Exclusive percentages are expressed among all adults who stopped or tried to stop smoking, not as a

177 percentage of those adults who used the particular method (e.g., 26.0% of all adults who stopped smoking

178 used e-cigarettes exclusively). Exclusive means the respondent selected that particular method but did not

179 select the other methods listed on the questionnaire (e.g., exclusive e-cigarette means reported using e-

180 cigarettes but not nicotine gum or lozenge, nicotine patch, nicotine, nasal spray/inhaler, varenicline,

181 bupropion, a quit line, or counseling).

- 182 d Estimates with an unweighted denominator or numerator less than 10, relative 95% CI width >160%, or
- degrees of freedom less than 8 are suppressed, consistent with the latest 2023 National Center for Health
- 184 Statistics standards for rates and counts (<u>https://www.cdc.gov/nchs/data/series/sr\_02/sr02-200.pdf</u>).

185 • Stopped smoking "completely" from 2021 through 2022 or tried from 2021 through 2022 and reported

- using any of e-cigarettes, nicotine gum/lozenge, nicotine patch, nicotine nasal spray/inhaler, varenicline,
   bupropion, quit line, counseling, or clinic/class/group.
- 188 <sup>f</sup> Stopped smoking "completely" from 2021 through 2022 or tried from 2021 through 2022 but did not report
- 189 using any of e-cigarettes, nicotine gum/lozenge, nicotine patch, nicotine nasal spray/inhaler, varenicline,
- 190 bupropion, quit line, counseling, or clinic/class/group.